

The Effect of Some Polymorphisms in Vitamin D Receptor Gene in Menopausal Women with Osteoporosis

MORTEZA DEGHAN¹, RAZIEH POURAHMAD-JAKTAJI²

ABSTRACT

Introduction: Vitamin D receptor gene is one of candidate genes related to osteoporosis expansion. The association of Apal, TaqI, BsmI polymorphisms in vitamin D receptor gene with bone metabolism and density has been area of interest in many studies.

Aim: This study was conducted to further investigate the association between the Apal, TaqI, BsmI polymorphisms and bone density. This study was analytical study. Centers for bone density measurement in southwestern Iran.

Materials and Methods: In this analytical study, 200 participants aged 45- and above 45-year-old women referring the centers of bone density measurement participated. The bone density of femoral neck and lumbar vertebrae was measured using dual-energy X-ray absorptiometry method. Based on t-score, the participants were assigned into patients (n=130) and healthy individuals (n=70). Different genotypes of Apal (AA/Aa/aa), TaqI (TT/Tt/tt), and BsmI (BB/Bb/bb) were determined by PCR-RFLP.

The data on bone density and PCR-RFLP were analysed by chi-square and ANOVA. Also, triad combination of the genotypes was statistically analysed. For each genotype combination, chi-square was run between the patients and control group and p-value was calculated.

Results: No significant association was seen between Apal polymorphism and bone density ($p>0.05$). TaqI and BsmI polymorphisms had a significant association with femoral neck's bone density ($p<0.05$), but these polymorphisms were not significantly associated with lumbar vertebrae's ($p>0.05$). Patients with homozygous dominant TT genotype had the least bone density in femoral neck compared to other genotypes. Lumbar vertebrae's bone density was similar in three TaqI genotypes. The patients with homozygous recessive bb genotype had the least bone density in femoral neck and lumbar vertebrae compared to other genotypes.

Conclusion: TaqI and BsmI polymorphisms could be desirable markers in diagnosis of women at risk of osteoporosis in the studied region in Iran. Therefore, these women will receive suitable medical treatment at proper time.

Keywords: DNA marker, Bone density, PCR-RFLP

INTRODUCTION

Osteoporosis is a serious, metabolic bone disorder that leads to increased susceptibility to fractures and decreased mechanical strength of the bones. Osteoporosis is a silent disease that is developed in millions of the people worldwide. Since osteoporosis is asymptomatic unless a fracture occurs, it is called silent thief [1-3].

It was estimated that over 200 million people suffer from osteoporosis around the world [4]. Osteoporosis-associated fractures impose a considerable economic burden on health system and this disease, if left untreated, results in serious and grueling outcomes [5]. It was reported that the worldwide annual incidence of hip fracture was about 1.7 million in 1992 [4]. Approximately 30% of all postmenopausal women have had osteoporosis in the United States and Europe. It was stated that the risk of hip fracture in these countries was even more than the risk of breast cancer in 2001 [6]. Studies on Asian women have indicated that bone density is lower in these women compared to European and the U.S women [7]. The highest prevalence of osteoporosis is observed in the elderly, particularly women, such that the investigations have demonstrated that women develop osteoporosis four times higher than men, but sometimes this disease has occurred in skeletal growth period and even adolescence [8].

Osteoporosis is a multifactorial disease and is related to interaction between genetic and environmental factors. The study of potential genetic predisposition to osteoporosis is highly important. Several works have reported that osteoporosis is associated with the polymorphisms of some genes [9,10]. Analyses have revealed that

vitamin D receptor (VDR), calcitonin receptor, Estrogen receptor (ER) gene, Type I collagen (COL1A1) gene, and Lactase (LCT) gene have the highest contribution to osteoporosis expansion [11]. Mineral homeostasis and bone metabolism are totally dependent on vitamin D. This vitamin plays its role through its receptor and vitamin D receptor (VDR) gene determines receptor structure. Therefore, VDR gene could be an important candidate gene for osteoporosis [12]. Gene mutation could influence function and be associated with potential development of osteoporosis [13]. Although a strong association has been offered between VDR genotypes and bone mineral density (BMD) in osteoporosis [14], inconsistent findings have been obtained on the possible association between postmenopausal bone loss and VDR genotype [12,15]. VDR gene is located on long arm of chromosome 12 (12q12-14). 10 exons and 8 interons have been determined on this gene's structure [16]. VDR polymorphisms consist of FokI, Apal, BsmI, TaqI, Cdx2, etc [17].

The Apal polymorphism (rs7975232) is located on interon 8. This polymorphism causes guanine nucleotide to be substituted with thymine (G→T) [18]. In the TaqI polymorphism, the nucleotide at position 352 is converted from thymine into cytosine (T352C). Therefore, ATT codon which encodes isoleucine is converted into the codon of another isoleucine, i.e. ATC [19,20]. In the VDR gene, the ability to cut by the Apal and TaqI enzymes leads to development of other genotypes as follows:

The genotypes of Apal: AA (absence of the position identifying the enzyme); Aa (heterozygous position of identifying the enzyme), and aa (existence of the position identifying the enzyme) and the

genotypes of TaqI: TT (absence of the position identifying the enzyme); Tt (heterozygous position of identifying the enzyme), and tt (existence of the position identifying the enzyme).

The BsmI polymorphism (rs1544410) is located on interon 8 of VDR gene. In this polymorphism, the nucleotide adenine is substituted with guanine (A→G) [18].

The relationship between the VDR genotypes and BMD may be different in various racial and geographical populations [21,22]. This study was conducted to investigate the association between the Apal, TaqI, and BsmI polymorphisms and bone density in 45 and over 45 year-old women in southwestern Iran.

MATERIALS AND METHODS

In this analytical study, blood samples were taken from 45- and over 45-year-old women referring centers for bone density measurement in southwestern Iran based on convenience sampling. In this study, based on Cockran formula 200 participants (130 patients and 70 healthy individuals) were investigated after their consent was obtained. Exclusion criteria were curtin consumption history, ovariectomy or premature ovarian failure, thyroid disease, calcium intake disorders, gastrointestinal and renal diseases and other diseases demonstrated to be associated with osteoporosis.

The bone density rate in lumbar vertebrae and femoral neck was measured by dual-energy X-ray absorptiometry (DEXA) method using Hologic QDR (Germany) and the values were determined by t-score. Then a 5 ml complete blood was taken for genetic examinations and collected in the tubes containing EDTA Anti-coagulation. The samples were kept at 20°C till the day of tests.

The genomic DNA was extracted using phenol-chloroform method. The polymorphisms of Apal, TaqI and BsmI were amplified from VDR gene using the primers designed by Gene Runner Software. The used primers are shown in [Table/Fig-1].

The materials in PCR reaction were as follows: 0.2 ml 10X buffer, 1.5 µl 50mM MgCl₂, 10 mM dNTP (2'-deoxynucleoside 5'-triphosphate) Mix, 0.7 µl 10 pmol/ml forward primer, 0.7 µl 10 pmol/ml reverse primer, 0.2 µl of Taq polymerase (5 U/µl), 3.2 µl of template DNA, and ddH₂O till the reaction volume reaches 25 µl.

PCR reactions were done for Apal and TaqI using the temperature gradient as follows:

95°C for 5 min as initial denaturation followed by 95°C for 50 seconds, 68.7°C for 45 seconds as the connection point, 72°C for 1 min as a 36-cycle extension, and finally 72°C for 5 min as final extension.

PCR reaction was done for BsmI per touchdown PCR using the temperature gradient as follows: 95°C for 3 min as initial denaturation followed by 95°C for 30 seconds, 56°C for 40 seconds and 72°C for 30 seconds for 8-cycle proliferation, and then 95°C for 40 seconds, 49°C for 40 seconds and 72°C for 30 seconds for 26-cycle amplification, and finally 72°C for 5 min as final extension. Thermocycler (ASTEC, PC818 Japan) was used.

After amplification, the fragments were digested using Apal, TaqI, and BsmI restriction enzymes (Fermentas).

The RFLP reaction for each of the polymorphisms (for 30-µl volume) were as follows: 17.5µl sterile water, 2µl 10X buffer, 10µl PCR product, and 0.5µl restriction Apal, TaqI and MVa12691 (BsmI) enzymes. Then, they were left at 37°C. The obtained products were reviewed on an 8% polyacrylamide gel and the genotype of Apal, TaqI and BsmI were determined.

STATISTICAL ANALYSIS

The data on bone density and PCR-RFLP were analysed by chi-square and ANOVA. Also, triad combination of the genotypes was statistically analysed. For each genotype combination, chi-square was run between the patients and control group and p-value was calculated.

RESULTS

In 200 samples there were 737 bp amplified fragments for Apal polymorphism, which produced two 520-bp and 217-bp fragments after digestion with Apal enzyme if the position of restriction site was present [Table/Fig-2].

The length of amplified fragment in TaqI was 737 bp and the fragments below were produced due to the presence of a mandatory secondary position of identifying the enzyme in normal conditions: the TT genotype produced two 494-bp and 243-bp fragments, Tt four 494-bp, 243-bp, 201-bp, and 293-bp fragments, and tt three 243-bp, 201-bp, and 293-bp fragments [Table/Fig-3].

The BsmI enzyme cut the samples with b allele (the bb genotype) and produced two 192-bp and 166-bp fragments. The samples with BB genotype remained unchanged and had a 358-bp band, and those with Bb genotype had 192-bp, 166-bp, and 358-bp fragments [Table/Fig-4].

In the patients, the frequency distribution of Apal genotypes was 79 (60.8%) individuals with Aa, followed by AA in 50 (38.5%) and aa in one (0.7%). In the control group it was 41 (58.6%) individuals with

polymorphism	The size of fragment	Primer type	5'-3' Primer sequences
Apal	737	F	CAGAGCATGGACAGGGAGCAA
		R	TCATGGCTGAGGTCTCAAGGG
TaqI	737	F	CAGAGCATGGACAGGGAGCAA
		R	TCATGGCTGAGGTCTCAAGGG
BsmI	358	F	GGGAGACGTAGCAAAAGG
		R	AGAGGTCAAGGGTCACTG

[Table/Fig-1]: The primers used.

polymorphism	The patients' genotype	Number	Femoral neck's T-score Mean±SD	Lumbar vertebrae's T-score Mean±SD
Apal polymorphism	AA	50	-1.29±0.34	-2.75±0.83
	Aa	79	-1.3±0.55	-2.83±0.50
	aa	1	-2.1±0	-2.9±0
	p-value		0.269	0.797
TaqI polymorphism	TT	57	-1.43±0.48	-2.80±0.47
	Tt	66	-1.2±0.48	-2.80±0.68
	tt	7	-1.27±0.35	-2.80±1.38
	p-value		0.025	0.999
BsmI polymorphism	BB	31	-1.14±0.26	-2.92±0.78
	Bb	70	-1.3±0.52	2.68±0.61
	bb	29	-1.48±0.53	-2.94±0.53
	p-value		0.025	0.091


[Table/Fig-2]: The association of Apal, TaqI, and BsmI polymorphisms with t-score in the patients.

Aa, followed by AA in 26 (37.1%) and aa in 3 (4.3%). By statistical analyses, there was no significant association between Apal polymorphism and bone density rate in femoral neck and lumbar vertebrae (p<0.05). In the patients, the frequency distribution of TaqI genotypes was 66 (50.8%) individuals with Tt, followed by TT in 57 (43.8%) and tt in seven (5.4%). In the control group it was 34 (48.5%) individuals with TT, followed by Tt in 30 (42.9%) and tt in 6 (8.6%). By statistical analyses, there was a significant association between TaqI polymorphism and bone density rate in femoral neck (p<0.05) and no significant association between TaqI polymorphism and bone density rate in lumbar vertebrae (p>0.05). The individuals with the homozygous dominant TT genotype had the lowest femoral neck's bone density rate and lumbar vertebrae's was the same in all genotypes.

In the patients, the frequency distribution of BsmI genotypes was 70 (53.8%) individuals with Bb, followed by BB in 31 (23.8%) and

Genotypic combination	T- score of the patients' femoral neck	T- score of the patients' lumbar vertebrae	The observed number/ patients	The expected number/ patients	The observed number/ controls	The expected number/ controls	Chi-Square	p-value
AABBTt	-1.1±0.19	-3.02±0.56	18	12	6	12	6	p<0.05
AABBtt	-1.27±0.49	-2.9±1.92	4	4	4	4	0	p<0.05
AABbTT	-1.6±0.43	-2.61±0.44	7	6	5	6	0.32	p<0.05
AABbTt	-1.41±0.32	-2.35±0.86	15	10.5	6	10.5	3.86	p<0.05
AAbbTT	-1.24±0.34	-3.04±0.67	5	4	3	4	0.5	p<0.05
AaBBTt	-1.16±0.17	-2.76±0.41	6	4	2	4	2	p<0.05
AaBbTT	-1.34±0.38	-2.64±0.34	19	15	11	15	2.14	p<0.05
AaBbTt	-1.14±0.68	-2.9±0.59	27	21	15	21	3.42	p<0.05
AaBbtt	-1.3±0	-2.9±0	1	1.5	2	1.5	1.4	p<0.05
AabbTT	-1.51±0.56	-2.92±0.52	23	16.5	10	16.5	5.2	p<0.05


[Table/Fig-3]: The comparison of the genotypic combinations between the control group and the patients.



[Table/Fig-4]: Polyacrylamide gel of the PCR-RFLP relevant to Apal genotypes. The 737 bp fragment was seen for AA and Aa genotypes. The 520-bp and 217-bp fragments were seen after digestion with Apal enzyme for Aa and aa genotypes. C+ and C- are abbreviation for control positive and control negative, respectively. Control positive and PCR show the 737 bp original amplified fragment. Control negative does not show any band as expected.

[Table/Fig-5]: Polyacrylamide gel of the PCR-RFLP relevant to TaqI genotypes. The TT genotype produced two 494-bp and 243-bp fragments. Tt genotype produced four 494-bp, 243-bp, 201-bp, and 293-bp fragments, and tt one produced three 243-bp, 201-bp, and 293-bp fragments. C+ and C- are abbreviation for control positive and control negative, respectively. Control positive and PCR show the 737 bp original amplified fragment. Control negative does not show any band as expected.

[Table/Fig-6]: Polyacrylamide gel of the PCR-RFLP relevant to BsmI genotypes. The bb genotype produced two 192-bp and 166-bp fragments. The BB genotype had a 358-bp band, and the Bb genotype had 192-bp, 166-bp, and 358-bp fragments. C+ is abbreviation for control positive. Control positive shows the 358 bp original amplified fragment.



[Table/Fig-7]: The results of DNA sequencing for Apal polymorphism. The results of sequence determination indicated that G→T occurred in heterozygous Aa individuals (GT), but this conversion did not occur in homozygous aa individuals.

[Table/Fig-8]: The results of DNA sequencing for TaqI polymorphism. The results of sequence determination indicated that T→C occurred in heterozygous Tt individuals (TC), but this conversion did not occur in homozygous tt individuals (TT).

[Table/Fig-9]: The results of sequence for BsmI polymorphism. (The results of sequence determination indicated that G→A occurred in both heterozygous Bb individuals (GA) and homozygous BB individuals (AA).

bb in 29 (22.3%). In the control group it was 39 (55.7%) individuals with Aa, followed by AA in 14 (20%) and aa in 17 (24.3%). By statistical analyses, there was a significant association between BsmI polymorphism and bone density rate in femoral neck ($p<0.05$) and no significant association between this polymorphism and bone density rate in lumbar vertebrae ($p>0.05$). The individuals with the

homozygous recessive Bb genotype had a lower bone density rate in femoral neck and lumbar vertebrae compared to the genotypes Bb and BB [Table/Fig-5].

The results of sequence of polymorphic position are shown in [Table/Fig-6-8]. For Apal polymorphism, substitution of guanine with thymine removes the restriction site completely in AA genotype. For

TaqI polymorphism, conversion of thymine into cytosine leads to generation of a restriction site in tt genotype. For BsmI polymorphism, substitution of adenine with guanine produces a restriction site in bb genotype.

The results of triad combination: 11 genotypic combinations were common between the patients and the control group. In view of p-value, there was a significant difference in frequency of only AABbTt, AABbTt, and AabbTT between the control group and the patients ($p < 0.05$). The individuals with AABbTt genotype had the highest bone density rate of lumbar vertebrae in the patients and those with AabbTT had the least bone density rate of femoral neck in the patients [Table/Fig-9].

DISCUSSION

Osteoporosis is a serious, metabolic bone disorder. Osteoporosis expansion can be related to VDR gene polymorphisms, including Apal, TaqI and BsmI polymorphisms. This study indicated that there was no significant association between Apal polymorphism and bone density rate in lumbar vertebrae and femoral neck; TaqI and BsmI polymorphisms were significantly associated with femoral neck's bone density rate, but not significantly associated with lumbar vertebrae's. In addition, the patients with homozygous recessive bb genotype had a lower bone density rate in femoral neck and lumbar vertebrae compared to the genotypes Bb and BB.

In similar works by Qin et al., on the association of different polymorphisms of VDR gene and estrogen receptor alpha with bone density in postmenopausal women, no significant association was noted between Apal polymorphism and bone density in femoral neck and lumbar vertebrae [23]. Zajickova et al., investigated the association of BsmI, Apal and TaqI polymorphisms with bone density in 114 Czech postmenopausal women with mean age of 62.5 ± 8.9 years. They argued that there was no significant association between these polymorphisms and bone density in any skeletal site and no significant difference in genotypic distribution was observed between the patients and the control group [24]. Uysal et al., also examined the association between BsmI, Apal, and TaqI and osteoporosis in 246 postmenopausal women in Turkey and found no significant association between Apal and TaqI polymorphisms and osteoporosis [25]. Shen et al., indicate that Apal, BsmI, TaqI and FokI polymorphisms may be not associated with the risk of fracture in postmenopausal women [26]. But, Mitra et al., examined 246 Indian postmenopausal women with mean age of 54.2 ± 3.4 -year-old and reported mean bone density in spine and femoral neck of the women with homozygous recessive AA genotype and homozygous dominant TT genotype was 10% higher than that of the women with the genotypes AA and tt [21].

Tamulaitiene et al., reported similar findings to those on BsmI polymorphism obtained in the present study. They stated there was no significant difference in the frequency of BsmI genotypes between the patients and the control group. Also, the BsmI polymorphism of VDR gene had a non significant, weak association with BMD and severe postmenopausal osteoporosis, which needed further investigations. In the patients with severe osteoporosis, the bone density of the individuals with the BB genotype was higher compared to those with the genotypes Bb and bb [27]. But, Ji et al., in a meta-analysis found that in the Caucasian cases with osteoporosis-related fracture, the frequency of homozygous recessive bb genotype was significantly lower [28]. Also, Garnerio et al., indicated an association between the increase in B allele and fracture frequency. The relative risk of such fractures in the women with heterozygous Bb genotype was 1.5 times higher and in the women with the homozygous dominant BB genotype was 2.1 times higher compared to the women carrying homozygous recessive bb genotype [29].

Langdahl et al., investigated the BsmI, Apal, and TaqI polymorphisms in 192 patients with osteoporosis and 207 healthy controls in Denmark and found the genotypes BB and Bb were

higher. Femoral neck's BMD was higher in the individuals with Bb genotype. They concluded that B allele of BsmI polymorphism was associated with decrease in bone density and the fractures due to osteoporosis [30]. Thakkinstian et al., did an extensive analysis on the association between BsmI polymorphism of VDR gene and bone density and found that B allele was significantly associated with lumbar vertebrae's bone density and also the individuals with the BB genotype had a lower bone density compared to those with the genotypes Bb and bb [31].

When comparing genotypes in the patients individually, the Aa genotype of Apal polymorphism had a bone density approximately similar to that of the AA genotype. For TaqI polymorphism in the patients, Tt genotype was similar to the two other genotypes in view of lumbar vertebrae's bone density and between the two other genotypes (TT, tt) in view of femoral necks. Therefore, since frequency of the genotypic combination AABbTt is low (15 of 130) in the patients, this combination could represent less likelihood of fracture in the individuals with this genotype compared to other patients.

In addition, of the three above-mentioned genotypic combinations, the individuals with genotypic combination of AabbTT had the lowest bone density of femoral neck and this genotypic combination was observed in 23 patients. When comparing the genotypes of each polymorphism individually, we observed that the Bb genotype of BsmI polymorphism and TT genotype of TaqI polymorphism had the lowest bone density of femoral neck compared to other relevant genotypes. Therefore, simultaneous study of two polymorphisms is more valuable than studying them separately, but the genotypes related to Apal polymorphism seem to yield little data on genotypic combinations. The same could be concluded for examining this polymorphism separately.

CONCLUSION

The study of genotypic combination of three polymorphisms does not yield the data inconsistent with those of studies on individual polymorphisms and simultaneous study of three polymorphisms could yield better data compared to study of individual polymorphisms. TaqI and BsmI polymorphisms could be good markers in identifying the women predisposed to osteoporosis in the region and even Iran, however larger and/or other populations need to be investigated to confirm these findings.

ACKNOWLEDGEMENTS

Hereby, we thank Research Deputy of University of Shahrekord, Research and Technology Deputy of Shahrekord University of Medical Sciences and Cellular and Molecular Research Center of Shahrekord University of Medical Sciences for cooperating in conduction of this work.

REFERENCES

- [1] Chan MF, Kwong WS, Zang YL, Wan PY. Evaluation of an osteoporosis prevention education programme for young adults. *J Adv Nurs*. 2007;57(3):270-85.
- [2] Alexandraki KI, Syriou V, Ziakas PD, Apostolopoulos NV, Alexandrakis AI, Piperi C. The knowledge of osteoporosis risk factors in a Greek female population. *Maturitas*. 2008;59(1):38-45.
- [3] Hazavehei SM, Taghdisi MH, Saidi M. Application of the Health Belief Model for osteoporosis prevention among middle school girl students, Garmsar, Iran. *Educ Health (Abingdon)*. 2007;20(1):23.
- [4] Cooper C, Comion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. *Osteoporos Int*. 1992;2(6):285-89.
- [5] Bonura F. Prevention, screening, and management of osteoporosis: an overview of the current strategies. *Postgrad Med*. 2009;121(4):5-17. doi: 10.3810/pgm.2009.07.2021.
- [6] Van Staa TP, Dennison EM, Leufkens HE, et al. Epidemiology of fracture in England and Wales. *Bone*. 2001;29:517-22.
- [7] Chang SF. A cross-sectional survey of calcium intake in relation to knowledge of osteoporosis and beliefs in young adult women. *Int J Nurs Pract*. 2006;12(1):21-27.
- [8] John J. Nutrition and bone health: In: Mahan LK, S Escott-Stump. Krause's food, Nutrition and diet therapy. 11th ed. Philadelphia: WB Saunders Co; 2004: 642-665.

- [9] Kou I, Takahashi A, Urano T, et al. Common variants in a novel gene, FONG on chromosome 2q33.1 confer risk of osteoporosis in Japanese. *PLoS ONE*. 2011;6(5): e19641.
- [10] Mendes AI, Mascarenhas MR, Matos S, et al. A WNK4 gene variant relates to osteoporosis and not to hypertension in the Portuguese population. *Mol Genet Metab*. 2011;102(4):465-69.
- [11] Marozik P, Mosse I, Ameliyanovich M, et al. Molecular and genetic mechanisms of predisposition to osteoporosis. *Gerontologija*. 2011;12(4):250-58.
- [12] Fang Y, Rivadeneira F, Meurs JBJ, Pols HAP, Ioannidis PA, Uitterlinden AG. Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: A meta analysis. *Bone*. 2006;39(4):938-45.
- [13] Qin G, Dong Z, Zeng P, Liu M, Liao X. Association of vitamin D receptor BsmI gene polymorphism with risk of osteoporosis: a meta-analysis of 41 studies. *Mol Biol Rep*. 2013;40(1):497-506.
- [14] Zintzaras E, Rodopoulou P, Koukoulis GN. BsmI, TaqI, Apal and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. *Dis Markers*. 2006;22(5-6):317-26.
- [15] Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, et al. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. *Ann Intern Med*. 2006;145(4):255-64.
- [16] Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear Vitamin D receptor: biological and molecular regulatory properties revealed. *J Bone Miner Res*. 1998;13(3):325-49.
- [17] Deng H, Liu F, Pan Y, Jin X, Wang H, Cao J. BsmI, TaqI, Apal, and FokI polymorphisms in the vitamin D receptor gene and periodontitis: a meta-analysis of 15 studies including 1338 cases and 1302 controls. *J Clin Periodontol*. 2011;38(3):199-207.
- [18] Ban Y, Taniyama M, Ban Y. Vitamin D receptor gene polymorphism is associated with Grave's disease in the Japanese population. *J Clin Endocrinol Metab*. 2000;85(12):4639-43.
- [19] Videman T, Gibbons LE, Battie MC, et al. The relative roles of intragenic polymorphisms of the vitamin D receptor gene in lumbar spine degeneration and bone density. *Spine*. 2001;26(3):E7-E12.
- [20] Videman T, Leppavuori J, Kaprio J. Intragenic polymorphisms of the vitamin D receptor gene associated with intervertebral disc degeneration. *Spine*. 1998;23:2477-85.
- [21] Mitra S, Desai M, Ikram Khathatay M. Vitamin D receptor gene polymorphisms and bone mineral density in postmenopausal Indian women. *Maturitas*. 2006;55(1):27-35.
- [22] McDonald CF, Zebaze RM, Seeman E. Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial. *Osteoporos Int*. 2006;17(10):1546-51.
- [23] Qin YJ, Zhang ZL, Huang QR, et al. Association of vitamin D receptor and estrogen receptor-alpha gene polymorphism with peak bone mass and bone size in Chinese women. *Acta Pharmacol Sin*. 2004;25(4):462-68.
- [24] Zajickova K, Zofkova I, Bahboub R, Krepelova A. Vitamin D receptor gene polymorphisms, bone mineral density and bone turnover: FokI genotype is related to postmenopausal bone mass. *Physiol Res*. 2002;51(5):501-09.
- [25] Uysal AR, Sahin M, Gursoy A, Gullu S. Vitamin D receptor gene polymorphism and osteoporosis in the Turkish population. *Genet Test*. 2008;12(4):591-94.
- [26] Shen H, Xie J, Lu H. Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis. *Climacteric*. 2014;17(4):319-24.
- [27] Tamulaitien M, Marozik P, Alekna V, et al. Association of VDR BsmI gene polymorphism, bone turnover markers and bone mineral density in severe postmenopausal osteoporosis. *Gerontologija*. 2012;13(4):206-13.
- [28] Ji GR, Yao M, Sun CY, Li ZH, Han Z. BsmI, TaqI, Apal and FokI polymorphisms in the vitamin D receptor (VDR) gene and risk of fracture in Caucasians: a meta-analysis. *Bone*. 2010;47(3):681-86.
- [29] Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. *Arthritis Rheum*. 2005;52(9):2822-29.
- [30] Langdahl B.L, Gravholt C.H, Brixen K, Eriksen E.F. Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures. *Eur J Clin Invest*. 2000;30(7):608-17.
- [31] Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. *J Bone Miner Res*. 2004;19(3):419-28.

PARTICULARS OF CONTRIBUTORS:

1. Associate Professor, Department of Orthopedics, Shahrekord University of Medical Sciences, Shahrekord, Iran.
2. Assistant Professor, Department of Genetics, University of Shahrekord, Shahrekord, Iran.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Razieh Pourahmad-Jaktaji,
Assistant Professor, Department of Genetics, Shahrekord University of Medical Sciences, Shahrekord, Iran.
E-mail : razieh_jaktaji@yahoo.com.

Date of Submission: **Oct 03, 2015**
Date of Peer Review: **Nov 09, 2015**
Date of Acceptance: **Dec 02, 2015**
Date of Publishing: **Jun 01, 2016**

FINANCIAL OR OTHER COMPETING INTERESTS: Shahrekord University of Medical Sciences, Grant number: 91-01-89-1432.